Importance Malignant primary brain tumors cause more than 15 000 deaths per year in the
United States. The annual incidence of primary malignant brain tumors is approximately 7 …

In the past decade, substantial advances have been made in understanding the biology of
tumour-associated macrophages (TAMs), and their clinical relevance is emerging. A …

Gliomas are the common type of brain tumors originating from glial cells. Epidemiologically,
gliomas occur among all ages, more often seen in adults, which males are more susceptible …

Immune-mediated anti-tumoral responses, elicited by oncolytic viruses and augmented with
checkpoint inhibition, may be an effective treatment approach for glioblastoma. Here in this …

Background Nearly all patients with newly diagnosed glioblastoma experience recurrence
following standard-of-care radiotherapy (RT)+ temozolomide (TMZ). The purpose of the …

Glioblastoma (GBM) is the most common high-grade primary malignant brain tumor with an
extremely poor prognosis. Given the poor survival with currently approved treatments for …

The main breakthrough in tumor immunotherapy was the discovery of immune checkpoint
(IC) proteins, which act as a potent suppressor of the immune system by a myriad of …

Despite advances in neurosurgery, chemotherapy and radiotherapy, glioblastoma remains
one of the most treatment-resistant CNS malignancies, and the tumour inevitably recurs. The …

Advances in hydrogel technology have unlocked unique and valuable capabilities that are
being applied to a diverse set of translational applications. Hydrogels perform functions …

A major rate-limiting step in developing more effective immunotherapies for GBM is our
inadequate understanding of the cellular complexity and the molecular heterogeneity of …